References
- Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348–354.
- Hobbs JR. Growth rates and responses to treatment in human myelomatosis. Br J Haematol 1969;16:607–617.
- Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92:143–144.
- Durie BG, Harousseau JL, Miguel JS, et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
- Kuhnemund A, Liebisch P, Bauchmuller K, et al ‘Light-chain escape-multiple myeloma’ - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477–484.
- Nowrousian MR, Brandhorst D, Sammet C, et al Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005;11:8706–8714.
- Balleari E, Ghio R, Falcone A, Musto P. Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leuk Lymphoma 2004;45:735–738.
- Pirrotta MT, Gozzetti A, Cerase A, et al Unusual discordant responses in two multiple myeloma patients during bortezomib treatment. Onkologie 2008;31:45–47.
- Magrangeas F, Cormier ML, Descamps G, et al Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 2004;103:3869–3875.
- Ayliffe MJ, Davies FE, de Castro D, Morgan GJ. Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica 2007;92:1135–1138.